BRIEF published on 09/10/2025 at 21:46, 2 months 24 days ago UZEDY® Obtains Approval in South Korea Following Success in the United States Schizophrenia UZEDY Teva Handok Medical Supply Korean Market
PRESS RELEASE published on 09/10/2025 at 21:41, 2 months 24 days ago Inside Information / Other news releases Teva Handok announces regulatory approval for UZEDY® in South Korea by Ministry of Food and Drug Safety, following successful US launch. Medincell's long-acting injectable for schizophrenia shows strong commercial performance Regulatory Approval Schizophrenia Medincell Commercial Performance Teva Handok
BRIEF published on 08/04/2025 at 14:05, 4 months ago Medincell Announces its 2025 General Meeting Governance General Meeting Resolutions Remuneration Medincell
BRIEF published on 07/30/2025 at 14:34, 4 months 5 days ago Medincell's Rising Revenue and Upcoming Submissions Schizophrenia Treatment Teva Partnership Medincell Revenue UZEDY Sales Olanzapine Submission
PRESS RELEASE published on 07/30/2025 at 14:29, 4 months 5 days ago INSIDE INFORMATION / OTHER NEWS RELEASES Medincell's partner Teva Pharmaceuticals raises 2025 revenue outlook for UZEDY® to $190–$200M and confirms Olanzapine LAI on track for submission in 2025 Revenue Outlook Medincell Teva Pharmaceuticals Olanzapine LAI Submission
BRIEF published on 07/30/2025 at 13:47, 4 months 5 days ago Medincell's UZEDY® and Olanzapine LAI Forecast Promising Financial Outcomes Schizophrenia Treatment Teva Pharmaceuticals Medincell Revenue Forecast UZEDY® Performance Olanzapine LAI Development
PRESS RELEASE published on 07/30/2025 at 13:42, 4 months 5 days ago Inside Information / Other news releases Medincell's partner Teva increases 2025 revenue outlook for UZEDY® to $190–$200M, plans olanzapine LAI submission. Company's innovative treatments aim to improve medicine accessibility Revenue Outlook Medincell Teva Pharmaceuticals Olanzapine LAI UZEDY
BRIEF published on 07/30/2025 at 11:43, 4 months 5 days ago Medincell Releases 2024-25 Universal Registration Document Shareholders Governance Financial Report CSR Medincell
PRESS RELEASE published on 07/30/2025 at 11:38, 4 months 5 days ago Annual financial and audit reports / Terms of availability of the annual financial report Medincell announces availability of its 2024-25 Universal Registration Document, including financial and CSR reports. Innovative treatments developed aim to improve effectiveness of medicines Financial Reports Universal Registration Document CSR Innovative Treatments Medincell
BRIEF published on 05/07/2025 at 15:17, 6 months 28 days ago Medincell's Growth in Antipsychotic Treatments FDA Filing Medincell Olanzapine LAI UZEDY Antipsychotics
Published on 12/05/2025 at 02:35, 3 hours 51 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 5 hours 26 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 7 hours 21 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 7 hours 26 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 03:30, 2 hours 56 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 6 hours 36 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 10 hours 1 minute ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 10 hours 11 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 11 hours 16 minutes ago SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance
Published on 12/04/2025 at 18:00, 12 hours 26 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 12 hours 41 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 12 hours 42 minutes ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 23 hours 25 minutes ago bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 12 hours ago Declaration of voting rights at the end of November 2025
